Schaeffers Research
01 Oct 2026, 15:44 UTC · 1d ago
Verdict
Headline takes no side. We score NKTR −0.80 across three claims — strongly bearish.
−0.80strongly bearish
More negative than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Nektar Therapeutics (NKTR) shares fell 19.1% to $48.97 following the presentation of long-term Phase 2b data for its alopecia areata and atopic dermatitis treatment.
Newarticle says 'today'
So whatThe negative reaction to Phase 2b data suggests a lower probability of success for Phase 3, risking significant downward revisions to future revenue estimates.
More negative than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Quantum-Si Inc (QSI) shares rose 25.2% to $1.34 after updates showed its next-generation Proteus platform outperforming the current system.
Newarticle says 'today'
So whatTechnical outperformance of the Proteus platform could accelerate the commercial adoption cycle, potentially improving Q4 revenue projections.
More positive than 93% of claims this week
Pacific Biosciences (PACB) shares rose 0.9% to $2.39 following a nearly 30% surge yesterday triggered by EpiSign's launch of EpiSign METRIC 5-base for its HiFi sequencing platform.
Priced insurged nearly 30% yesterday
So whatThe initial catalyst is already absorbed, leaving the stock to trade based on the actual adoption rate of the 5-base platform over the coming months.
More positive than 66% of claims this week
Which stocks this story touches
More negative than 85% of ticker scores this week
The stock price dropped over 19% following the presentation of Phase 2b data, with traders leaning bearish.
More positive than 82% of ticker scores this week
The stock surged over 25% following reports that its next-generation Proteus platform outperformed the current system.
More positive than 66% of ticker scores this week
The stock remains up following a massive surge yesterday linked to the launch of EpiSign METRIC 5-base.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
12h ago
−28.0%
Price agrees with the score
$43.60 vs $60.55 close before publication (Sep 30) · not market-adjusted
NKTR chart →
